×

Indications

Prolia® is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal Read More

Prolia® is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia® reduces the incidence of vertebral, nonvertebral, and hip fractures.

Prolia® is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

Prolia® is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. In these patients Prolia® also reduced the incidence of vertebral fractures.

Prolia® is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. Close

Financial Assistance and Support Options for Your Prolia® Patients

For eligible patients who are prescribed Prolia®, there may be co-pay support or other programs available to help ensure they have access to their medication.

With the Prolia® Co-pay Card, eligible patients with commercial insurance can pay $25 or less*

Specifically designed for patients on Prolia® for postmenopausal or male osteoporosis patients at high risk for fracture
  • No income eligibility requirement
  • Reduce OOP costs under the medical or pharmacy benefit
  • Applies to deductible, co-insurance, and/or co-pay for Prolia®†
To check a patient’s eligibility and to renew a Prolia® Co-pay Card online, go to ProliaSupport.com
  • *Eligibility criteria and limitations apply.
  • This program does not provide support for any physician-related services associated with administration of Prolia®.

Referrals to Independent Co-pay Foundations

Amgen Assist® can refer patients, as a courtesy, to independent co-pay foundations.

  • ‡Provided through independent charitable patient assistance programs; program eligibility is based on the charity's criteria. Amgen has no control over independent, third-party programs and provides referrals as a courtesy only.

For eligible uninsured or underinsured patients, Prolia® may be available from the Amgen Safety Net Foundation at no cost

The Amgen Safety Net Foundation

The Amgen Safety Net Foundation supports uninsured patients and certain underinsured patients who do not have coverage for their Amgen medication and have a financial need. Qualifying uninsured patients must not be eligible for Medicaid, Medicare, or any other financial support options.

Visit www.amgensafetynetfoundation.com or call 1-888-762-6436

For patients with breast or prostate cancer treatment–induced bone loss due to hormone ablation therapy

Explore Amgen Assist 360™ for co-pay support and more

Amgen Assist 360™
can help you and your
patients find co-pay and
reimbursement assistance,
track benefit verifications,
and access state-specific
payer policy information.

Visit Amgen Assist 360™ to:

  • Find co-pay and reimbursement resources for patients with different kinds of insurance, or no insurance at all
  • Submit, store, and retrieve benefit verifications for your patients
  • Connect with an Amgen Reimbursement Counselor or schedule a visit with a Field Reimbursement Specialist